Real-time Estimate
Cboe BZX
02:02:22 2024-05-10 pm EDT
5-day change
1st Jan Change
9.315
USD
-1.74%
-10.34%
-34.28%
Presenter SpeechAndrew Galler (Analysts)All right. Good afternoon, everyone. I'm Andrew Geller...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating
11:45am
MT
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
May. 09
MT
Transcript : Amicus Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
Amicus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
May. 09
CI
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating
Mar. 18
MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing
Mar. 05
MT
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises
Feb. 28
MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04
Feb. 28
MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
Feb. 28
CI
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing
Feb. 08
MT
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing
Jan. 24
MT
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing
Jan. 18
MT
Amicus Therapeutics Insider Sold Shares Worth $934,659, According to a Recent SEC Filing
Jan. 12
MT
Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing
Jan. 10
MT
Transcript : Amicus Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:15 PM
Jan. 08
Amicus Therapeutics Sees Revenue Growth of 21% in 2023
Jan. 08
MT
Amicus Therapeutics, Inc. Announces Unaudited Preliminary Revenue Results for the Fourth Quarter and Full Year of 2023
Jan. 07
CI
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024
Jan. 07
CI
Amicus Therapeutics Insider Sold Shares Worth $734,007, According to a Recent SEC Filing
Jan. 05
MT
Amicus Therapeutics Insider Sold Shares Worth $490,411, According to a Recent SEC Filing
Dec. 29
MT
Amicus Therapeutics Insider Sold Shares Worth $253,542, According to a Recent SEC Filing
Dec. 21
MT
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight
Dec. 20
DJ
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
More about the company
Last Close Price
9.48
USD
Average target price
18.56
USD
Spread / Average Target
+95.73%
Consensus
1st Jan change
Capi.
-34.28% 2.81B +18.25% 47.02B +48.77% 41.86B +0.60% 41.76B -4.27% 28.8B +11.85% 26.05B -21.96% 19.15B +4.00% 12.55B +28.75% 12.34B -4.34% 11.82B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1